Bristol-Myers Squibb (NYSE:BMY) Shares Sold by S.A. Mason LLC

S.A. Mason LLC trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 20.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,930 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. S.A. Mason LLC’s holdings in Bristol-Myers Squibb were worth $202,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. OFI Invest Asset Management acquired a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at $25,000. True Wealth Design LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth about $26,000. Milestone Investment Advisors LLC bought a new stake in Bristol-Myers Squibb in the third quarter worth about $27,000. Coppell Advisory Solutions LLC acquired a new stake in Bristol-Myers Squibb during the second quarter valued at approximately $28,000. Finally, Blue Bell Private Wealth Management LLC increased its holdings in shares of Bristol-Myers Squibb by 61.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 200 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of recent research reports. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Bank of America downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Wells Fargo & Company lowered their price objective on shares of Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 6th. Finally, Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their target price for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $61.12.

Bristol-Myers Squibb Trading Up 1.3 %

Bristol-Myers Squibb stock opened at $53.25 on Thursday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. The company has a market capitalization of $107.92 billion, a price-to-earnings ratio of 13.80, a PEG ratio of 1.58 and a beta of 0.38. The company’s fifty day moving average price is $50.73 and its two-hundred day moving average price is $52.43. Bristol-Myers Squibb has a one year low of $47.58 and a one year high of $71.07.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.55 by $0.15. The company had revenue of $11.48 billion for the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter last year, the company posted $1.82 earnings per share. On average, analysts forecast that Bristol-Myers Squibb will post 6.61 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 4.51%. Bristol-Myers Squibb’s payout ratio is 62.18%.

Bristol-Myers Squibb announced that its board has authorized a stock repurchase plan on Thursday, December 7th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to repurchase up to 2.9% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.